Results of lamivudine therapy for HBe antigen positive hepatitis (in the West)

Journal of Hepatology

Volumn 39, Issue SUPPL. 1, 2003, Pages

  Heathcote, Jenny ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; HEPATITIS B ANTIGEN; LAMIVUDINE; PLACEBO; VIRUS DNA;

AMINOTRANSFERASE BLOOD LEVEL; CANCER RISK; CELL ACTIVATION; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE EXACERBATION; DISEASE MARKER; DNA DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FIBROSIS; GENERAL CONDITION IMPROVEMENT; HEPATITIS B; HUMAN; INFLAMMATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER HISTOLOGY; NORTH AMERICA; PRIORITY JOURNAL; REMISSION; RISK FACTOR; SCORING SYSTEM; SEROCONVERSION; SIDE EFFECT; STELLATE CELL; VIRUS REPLICATION;

EID: 0141526144     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(03)00196-x     Document Type: Conference Paper

References (8)

1. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HWL, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
2. Jonas MM, Kelley DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13.
3. Zollner B, Peterson J, Schroter M, Laufs R, Schoder V, Feucht HH. Twenty-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001;357:934-5.
4. Zollner B, Peterson J, Schafer P, Schroter M, Laufs R, Sterneck M, et al. Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment. Clin Infect Dis 2002;34:1273-7.
5. Akuta N, Suzuki F, Kobayashi M, Tsubota A, Suzuki Y, Hosaka T, et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 2003;38:315-21.
6. Kweon YO, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burkhardt E, et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001;35:749-55.
7. Honkoop P, De Man RA, Niesters GM, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-9.
8. Dienstag J, Goldin RD, Heathcote EJ, Hann HWL, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-17.